Eyeing Terrorist Potential, Pentagon Seeks Vaccine Against Cold War-Era Bioweapon

"Q-fever" bacteria are seen through a laboratory microscope as they grow inside a biological cell. The U.S. Defense Department plans next week to lead a discussion with potential developers of a new vaccine against the possible bioterrorism agent.
National Journal
Diane Barnes, Global Security Newswire
Add to Briefcase
See more stories about...
Diane Barnes, Global Security Newswire
Nov. 27, 2013, 10:02 a.m.

WASH­ING­TON — The U.S. De­fense De­part­ment is get­ting set to push for a new vac­cine against “Q-fever” bac­teria, an agent with a repu­ta­tion as a po­ten­tial ter­ror­ism tool ac­quired in part through its his­tory as a gov­ern­ment-made bio­lo­gic­al weapon.

The Pentagon’s De­fense Threat Re­duc­tion Agency is plan­ning an on­line for­um on Dec. 5 to fa­cil­it­ate con­ver­sa­tion with po­ten­tial de­velopers of a vac­cine against Q fever, which is also known by the bac­teria’s form­al des­ig­na­tion, Cox­i­ella bur­netii.

The United States in­vest­ig­ated the agent’s war­fare po­ten­tial and the So­viet Uni­on fully weapon­ized it dec­ades ago, long be­fore both coun­tries form­ally de­nounced bio­lo­gic­al arms in the 1970s. The dis­ease also oc­curs in nature and has af­fected hun­dreds of U.S. troops de­ployed over­seas.

It can pro­duce fever, pneu­mo­nia, and nu­mer­ous oth­er symp­toms as­so­ci­ated with a vari­ety of patho­gens.

Cer­tain an­ti­bi­ot­ics are con­sidered ef­fect­ive against the bac­teria, but no vac­cine is presently sold in the United States, ac­cord­ing to the Fed­er­a­tion of Amer­ic­an Sci­ent­ists. An ex­ist­ing vac­cin­a­tion avail­able abroad re­portedly can cause side ef­fects such as abs­cesses and swollen joints.

The United States “should def­in­itely have a Q fever vac­cine,” Amesh Adalja, a seni­or as­so­ci­ate with the Cen­ter for Health Se­cur­ity at the Uni­versity of Pitt­s­burgh Med­ic­al Cen­ter, said in a phone in­ter­view. “This is still a dis­ease that has some pub­lic health bur­den, in ad­di­tion to its po­ten­tial use as a bioweapon.”

The U.S.-led oc­cu­pa­tion of Ir­aq led to roughly 200 “acute” Q-fever cases among U.S. sol­diers, the Cen­ters for Dis­ease Con­trol and Pre­ven­tion re­por­ted earli­er this year.

Those in­fec­tions ap­peared to res­ult from un­in­ten­tion­al ex­pos­ure to an­im­al car­ri­ers or bac­teria swept up by heli­copter ro­tors. Such nat­ur­ally oc­cur­ring cases rarely cause death, but Adalja sug­ges­ted the agent could prove more dan­ger­ous if in­cor­por­ated in a weapon.

Q-Fever bac­teria in­fec­ted but re­portedly did not kill any con­scien­tious war ob­ject­ors de­lib­er­ately ex­posed to the agent dur­ing U.S. Army ex­per­i­ments in the 1950s.

The United States has been eye­ing a new Q-fever vac­cine for sev­er­al years. However, the agent’s status as a po­ten­tial bi­o­ter­ror­ism tool is fairly new, re­l­at­ive to how long it has been an es­tab­lished bio­lo­gic­al weapon. CDC of­fi­cials only began track­ing Q-fever in­fec­tions in 1999, as the Clin­ton ad­min­is­tra­tion was in­creas­ing the na­tion’s fo­cus on bio­lo­gic­al ter­ror­ism as a na­tion­al-se­cur­ity threat.

A CDC list of po­ten­tial bi­o­ter­ror­ism agents and dis­eases, which in­cludes Q fever, “is de­rived al­most solely from the U.S. and So­viet bioweapons pro­grams,” Adalja said. He sug­ges­ted that the U.S. gov­ern­ment is “sub­stan­tially” more likely to fund de­vel­op­ment of vac­cines and treat­ments for such agents than for patho­gens nev­er in­volved in gov­ern­ment bio­lo­gic­al-weapons pro­grams.

Agents more than dan­ger­ous than Q-fever may have emerged since the Cold-War height of the U.S. and So­viet bio­lo­gic­al-weapons pro­grams, but the es­tab­lished track re­cord of his­tor­ic­al bio­lo­gic­al arms could make them par­tic­u­larly at­tract­ive to would-be bi­o­ter­ror­ists, Adalja said.

This art­icle was pub­lished in Glob­al Se­cur­ity News­wire, which is pro­duced in­de­pend­ently by Na­tion­al Journ­al Group un­der con­tract with the Nuc­le­ar Threat Ini­ti­at­ive. NTI is a non­profit, non­par­tis­an group work­ing to re­duce glob­al threats from nuc­le­ar, bio­lo­gic­al, and chem­ic­al weapons.

What We're Following See More »
STARTS LEGAL FUND FOR WH STAFF
Trump to Begin Covering His Own Legal Bills
1 days ago
THE DETAILS
DISCUSSED THE MATTER FOR A NEW BOOK
Steele Says Follow the Money
1 days ago
STAFF PICKS

"Christopher Steele, the former British intelligence officer who wrote the explosive dossier alleging ties between Donald Trump and Russia," says in a new book by The Guardian's Luke Harding that "Trump's land and hotel deals with Russians needed to be examined. ... Steele did not go into further detail, Harding said, but seemed to be referring to a 2008 home sale to the Russian oligarch Dmitry Rybolovlev. Richard Dearlove, who headed the UK foreign-intelligence unit MI6 between 1999 and 2004, said in April that Trump borrowed money from Russia for his business during the 2008 financial crisis."

Source:
BRITISH PUBLICIST CONNECTED TO TRUMP TOWER MEETING
Goldstone Ready to Meet with Mueller’s Team
1 days ago
THE LATEST

"The British publicist who helped set up the fateful meeting between Donald Trump Jr. and a group of Russians at Trump Tower in June 2016 is ready to meet with Special Prosecutor Robert Mueller's office, according to several people familiar with the matter. Rob Goldstone has been living in Bangkok, Thailand, but has been communicating with Mueller's office through his lawyer, said a source close to Goldstone."

Source:
SPEAKING ON RUSSIAN STATE TV
Kislyak Says Trump Campaign Contacts Too Numerous to List
1 days ago
THE LATEST

"Russian Ambassador Sergey Kislyak said on Wednesday that it would take him more than 20 minutes to name all of the Trump officials he's met with or spoken to on the phone. ... Kislyak made the remarks in a sprawling interview with Russia-1, a popular state-owned Russian television channel."

Source:
“BLOWING A SURE THING”
Sabato Moves Alabama to “Lean Democrat”
2 days ago
WHY WE CARE
×
×

Welcome to National Journal!

You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.

Login